Marks Lab

Home

Our research focuses on the generation of recombinant antibodies, mostly fully human, that can be used in the diagnosis and treatment of cancers and other human diseases, or to capture or neutralize toxins. We create antibody display libraries in single-chain variable fragment domain format (scFv) or fragment antigen-binding domain (Fab) format and express them in phage or yeast display platforms. Lead antibody candidates are isolated from these libraries by successive rounds of selection against natural or recombinant proteins or other soluble target antigens, or on specific cell lines. Selected antibody leads are expressed as fragments, full-length immunoglobulin, or in a designed molecular format via mammalian cell line or other protein expression systems for further in-vivo and in-vitro characterization.

Research

We create antibody display libraries by obtaining immunoglobulin (Ig) heavy and light chain variable region genes from mRNA that was prepared from human volunteers or immunized animals, or using chemically synthesized genes. These genes are cloned into phage display or yeast display vectors for antibody fragment display, either on the surface of phage or on yeast. 

Yeast surface display is also used for the construction and display of antigen cDNA libraries constructed from target cell lines, and for display of recombinant antigens to be targeted by antibodies. The cDNA libraries are used for identification of antigens bound by antibodies that have been selected on tumor cell lines. Recombinant target antigens displayed on yeast include the extracellular domains of receptor tyrosine kinases, Fc receptors, engineered integrin domains, and nontoxic domains of protein toxins, which are used for antibody selection and mapping the epitopes of the selected antibodies.

Recombinant scFv and Fab antibody fragments are expressed in E. coli K12 strains containing bacterial expression plasmids, and then purified from culture. To make full-length antibody, Ig genes are cloned into a mammalian expression vector where expression is driven by the CMV promoter. Vector DNA is transfected into CHO cells for stable expression, or COS7 or HEK293 cells for transient expression. Cloning and mammalian expression is also done for some cell surface proteins used as antigens for antibody selection, including integrin avb8 and TGF beta, extracellular domains of the oncogenic receptor tyrosine kinases (RTKs) such as EGFR, ErbB2, ErbB3, ErbB4, and EpHA2.

In vitro characterization of selected antibody clones is performed by assays against their targets, including FACS, ELISA, surface plasmon resonance, quartz crystal microbalance, kinetic exclusion assay (KinExA), meso-scale electrochemiluminescence (MSD), and EM (electron microscopy). Antibody fragments are also crystallized in complex with their targets for structural analysis.

Publications

Marks Lab: Selected Publications, 11/9/2018 (search and expanded by Dr. Jianlong Lou)

Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, Ito S, Yanagisawa H, Hashimoto M, Ma R, Levine MD, Publicover J, Potts R, Jespersen JM, Campbell MG, Conrad F, Marks JD, Cheng Y, Baron JL, Nishimura SL. Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. JCI Insight. 2018 Oct 18;3(20). pii: 122591. doi: 10.1172/jci.insight.122591. [Epub ahead of print] PubMed PMID: 30333313

Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH. Antibody engineering to improve manufacturability. Protein Expr Purif. 2018 Sep;149:75-83. doi: 10.1016/j.pep.2018.04.003. Epub 2018 Apr 12. PubMed PMID: 29655788

Cormier A, Campbell MG, Ito S, Wu S, Lou J, Marks J, Baron JL, Nishimura SL, Cheng Y. Cryo-EM structure of the αvβ8 integrin reveals a mechanism for stabilizing integrin extension. Nat Struct Mol Biol. 2018 Jul 30. PMID: 30061598.

Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD. A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. Toxins (Basel). 2018 Mar 1;10(3). pii: E105. doi: 10.3390/toxins10030105. PubMed PMID: 29494481; PubMed Central PMCID: PMC5869393

Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD. A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Toxins (Basel). 2018 Feb 15;10(2). pii: E84. doi: 10.3390/toxins10020084. PubMed PMID: 29462889; PubMed Central PMCID: PMC5848185

Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD. Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel. 2018 Jan 1;31(1):17-28. doi: 10.1093/protein/gzx063. PubMed PMID: 29301020

Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS One. 2017 Mar 21;12(3):e0174187. doi: 10.1371/journal.pone.0174187. eCollection 2017. PubMed PMID: 28323873; PubMed Central PMCID: PMC5360321

Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs. 2017 Jan;9(1):58-67. doi: 10.1080/19420862.2016.1259047. Epub 2016 Nov 17. PubMed PMID: 27854147; PubMed Central PMCID: PMC5240644

Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. J Infect Dis. 2016 May 15;213(10):1606-14. doi: 10.1093/infdis/jiv770. Epub 2016 Mar 1. PubMed PMID: 26936913; PubMed Central PMCID: PMC4837907

Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pèlegrin A, Poul MA. Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5. Mol Cancer Ther. 2015 Nov;14(11):2595-605. doi: 10.1158/1535-7163.MCT-15-0321. Epub 2015 Sep 10. PubMed PMID: 26358753; PubMed Central PMCID: PMC6013065

Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B. Toxins (Basel). 2015 Aug 26;7(9):3405-23. doi: 10.3390/toxins7093405. PubMed PMID: 26343720; PubMed Central PMCID: PMC4591640

Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia. 2016 Mar;30(3):692-700. doi: 10.1038/leu.2015.231. Epub 2015 Aug 19. PubMed PMID: 26286117

Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD. Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity. PLoS One. 2015 Aug 14;10(8):e0135306. doi: 10.1371/journal.pone.0135306. eCollection 2015. PubMed PMID: 26275214; PubMed Central PMCID: PMC4537209

Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL. TGF-ß-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease. J Immunol. 2015 Aug 01; 195(3):1182-90. PMID: 26109638; PMCID: PMC4506848.

Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL. Transforming Growth Factor-ß and Interleukin-1ß Signaling Pathways Converge on the Chemokine CCL20 Promoter. J Biol Chem. 2015 Jun 05; 290(23):14717-28. PMID: 25918170; PMCID: PMC4505537.

Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng Des Sel. 2015 Oct;28(10):307-16. doi: 10.1093/protein/gzv024. Epub 2015 May 19. PubMed PMID: 25991864; PubMed Central PMCID: PMC4607741

D'Souza JW, Reddy S, Goldsmith LE, Shchaveleva I, Marks JD, Litwin S, Robinson MK. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS One. 2014 Nov 11;9(11):e112376. doi: 10.1371/journal.pone.0112376. eCollection 2014. PubMed PMID: 25386657; PubMed Central PMCID: PMC4227695

Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y. High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One. 2014 Oct 29;9(10):e111339. doi: 10.1371/journal.pone.0111339. eCollection 2014. PubMed PMID: 25353955; PubMed Central PMCID: PMC4213037

Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther. 2014 Nov;13(11):2607-17. doi: 10.1158/1535-7163.MCT-14-0363. Epub 2014 Aug 20. PubMed PMID: 25143449; PubMed Central PMCID: PMC4221648

Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM. Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins. Analyst. 2014 Oct 21;139(20):5093-102. doi: 10.1039/c4an01270d. Epub 2014 Aug 12. PubMed PMID: 25112421

Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL. Selective targeting of TGF-β activation to treat fibroinflammatory airway disease. Sci Transl Med. 2014 Jun 18;6(241):241ra79. doi: 10.1126/scitranslmed.3008074. PubMed PMID: 24944194; PubMed Central PMCID: PMC4341974

Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 2014 May;9(5):664-74. doi: 10.1002/biot.201300550. Epub 2014 Mar 18. PubMed PMID: 24644233; PubMed Central PMCID: PMC4073886

Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 2014 Apr 2;588(7):1087-93. doi: 10.1016/j.febslet.2014.02.034. Epub 2014 Feb 25. PubMed PMID: 24583011; PubMed Central PMCID: PMC4067265

Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S. RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin. Talanta. 2013 Dec 15; 117:273-80. PMID: 24209341; PMCID: PMC3909959.

Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J. 2013 Jul 1;453(1):37-47. doi: 10.1042/BJ20130391. PubMed PMID: 23621114

Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM. Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem. 2012 Nov 15;430(2):185-92. doi: 10.1016/j.ab.2012.08.021. Epub 2012 Aug 27. PubMed PMID: 22935296; PubMed Central PMCID: PMC3589981

Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem. 2012 Nov 15;430(2):141-50. doi: 10.1016/j.ab.2012.08.005. Epub 2012 Aug 21. PubMed PMID: 22922799; PubMed Central PMCID: PMC4209713

Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB. N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano. 2012 Aug 28;6(8):6675-80. doi: 10.1021/nn301134z. Epub 2012 Aug 6. PubMed PMID: 22830952; PubMed Central PMCID: PMC3435507

Zhou Y, Zhao L, Marks JD. Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys. 2012 Oct 15;526(2):107-13. doi: 10.1016/j.abb.2012.05.007. Epub 2012 May 22. Review. PubMed PMID: 22627065; PubMed Central PMCID: PMC4209712

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther. 2012 Jul;11(7):1467-76. doi: 10.1158/1535-7163.MCT-11-1038. Epub 2012 May 7. PubMed PMID: 22564724; PubMed Central PMCID: PMC4209485

Liu YY, Rigsby P, Sesardic D, Marks JD, Jones RG. A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem. 2012 Jun 1;425(1):28-35. doi: 10.1016/j.ab.2012.02.038. Epub 2012 Mar 6. PubMed PMID: 22406430

Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 2012;502:139-66. doi: 10.1016/B978-0-12-416039-2.00007-0. PubMed PMID: 22208985

Zhou Y, Marks JD. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol. 2012;502:43-66. doi: 10.1016/B978-0-12-416039-2.00003-3. PubMed PMID: 22208981; PubMed Central PMCID: PMC4180867

Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012 Jan;11(1):143-53. doi: 10.1158/1535-7163.MCT-11-0519. Epub 2011 Nov 16. PubMed PMID: 22090420

Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem. 2011 Nov 15;12:58. doi: 10.1186/1471-2091-12-58. PubMed PMID: 22085466; PubMed Central PMCID: PMC3250939

Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem. 2012 Feb 15;421(2):351-61. doi: 10.1016/j.ab.2011.09.030. Epub 2011 Oct 6. PubMed PMID: 22037290; PubMed Central PMCID: PMC4209596

Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SK. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem. 2011 Dec 23;286(51):44218-33. doi: 10.1074/jbc.M111.290783. Epub 2011 Oct 14. PubMed PMID: 22002064; PubMed Central PMCID: PMC3243554

Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin avß8-mediated activation of TGF-ß. J Clin Invest. 2011 Jul; 121(7):2863-75. PMID: 21646718; PMCID: PMC3223836.

McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun;14(3):336-47. doi: 10.1007/s11307-011-0500-8. PubMed PMID: 21630083; PubMed Central PMCID: PMC3227780

Gray SA, Barr JR, Kalb SR, Marks JD, Baird CL, Cangelosi GA, Miller KD, Feldhaus MJ. Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes. Biotechnol Bioeng. 2011 Oct;108(10):2456-67. doi: 10.1002/bit.23196. Epub 2011 May 12. PubMed PMID: 21538339; PubMed Central PMCID: PMC3203252

Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011 Mar 15;71(6):2250-9. doi: 10.1158/0008-5472.CAN-10-2277. PubMed PMID: 21406401; PubMed Central PMCID: PMC3077882

Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011 Mar 15;17(6):1509-20. doi: 10.1158/1078-0432.CCR-10-1654. Epub 2010 Dec 21. PubMed PMID: 21177408; PubMed Central PMCID: PMC3060271

Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel. 2011 Mar;24(3):321-31. doi: 10.1093/protein/gzq111. Epub 2010 Dec 13. PubMed PMID: 21149386; PubMed Central PMCID: PMC3038462

Zhou Y, Zou H, Zhang S, Marks JD. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol. 2010 Nov 19;404(1):88-99. doi: 10.1016/j.jmb.2010.09.006. Epub 2010 Sep 17. PubMed PMID: 20851130; PubMed Central PMCID: PMC4195448

Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One. 2010 Aug 17;5(8):e12237. doi: 10.1371/journal.pone.0012237. PubMed PMID: 20808925; PubMed Central PMCID: PMC2923190

Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res. 2010 Jul 20;2(4):368-80. PubMed PMID: 20733947; PubMed Central PMCID: PMC2923861

Crépin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010 Jul 1;70(13):5497-506. doi: 10.1158/0008-5472.CAN-10-0938. Epub 2010 Jun 8. PubMed PMID: 20530676

Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1529-38. doi: 10.1007/s00259-010-1433-1. Epub 2010 Apr 1. PubMed PMID: 20354850; PubMed Central PMCID: PMC2903645

Lou J, Geren I, Garcia-Rodriguez C, Forsyth CM, Wen W, Knopp K, Brown J, Smith T, Smith LA, Marks JD. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel. 2010 Apr;23(4):311-9. doi: 10.1093/protein/gzq001. Epub 2010 Feb 15. PubMed PMID: 20156888; PubMed Central PMCID: PMC2841544

Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS. Tumor detection by imaging proteolytic activity. Cancer Res. 2010 Feb 15;70(4):1505-12. doi: 10.1158/0008-5472.CAN-09-1640. Epub 2010 Feb 9. PubMed PMID: 20145119; PubMed Central PMCID: PMC2823079

Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol. 2010 Apr 9;397(4):1106-18. doi: 10.1016/j.jmb.2010.01.070. Epub 2010 Feb 6. PubMed PMID: 20138889; PubMed Central PMCID: PMC2903050

Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res. 2009 Dec 1;69(23):8987-95. doi: 10.1158/0008-5472.CAN-09-2693. Epub 2009 Nov 24. PubMed PMID: 19934334

Cheng LW, Stanker LH, Henderson TD 2nd, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun. 2009 Oct;77(10):4305-13. doi: 10.1128/IAI.00405-09. Epub 2009 Aug 3. PubMed PMID: 19651864; PubMed Central PMCID: PMC2747958

Warner MG, Grate JW, Tyler A, Ozanich RM, Miller KD, Lou J, Marks JD, Bruckner-Lea CJ. Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron. 2009 Sep 15;25(1):179-84. doi: 10.1016/j.bios.2009.06.031. Epub 2009 Jun 26. PubMed PMID: 19643593; PubMed Central PMCID: PMC2728038

Ozanich RM Jr, Bruckner-Lea CJ, Warner MG, Miller K, Antolick KC, Marks JD, Lou J, Grate JW. Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Anal Chem. 2009 Jul 15;81(14):5783-93. doi: 10.1021/ac9006914. PubMed PMID: 19530657

Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One. 2009;4(4):e5355. doi: 10.1371/journal.pone.0005355. Epub 2009 Apr 28. PubMed PMID: 19399171; PubMed Central PMCID: PMC2670495

Grate JW, Warner MG, Ozanich RM Jr, Miller KD, Colburn HA, Dockendorff B, Antolick KC, Anheier NC Jr, Lind MA, Lou J, Marks JD, Bruckner-Lea CJ. Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format. Analyst. 2009 May;134(5):987-96. doi: 10.1039/b900794f. Epub 2009 Mar 5. PubMed PMID: 19381395

Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol. 2009;525:1-27, xiii. doi: 10.1007/978-1-59745-554-1_1. PubMed PMID: 19252861; PubMed Central PMCID: PMC3402212

Zhou Y, Marks JD. Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol. 2009;525:145-60, xv. doi: 10.1007/978-1-59745-554-1_7. PubMed PMID: 19252832

Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl). 2009 May;87(5):507-14. doi: 10.1007/s00109-009-0446-3. Epub 2009 Feb 14. PubMed PMID: 19219419; PubMed Central PMCID: PMC2796542

Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol. 2009 Sep;64(4):741-51. doi: 10.1007/s00280-008-0923-3. Epub 2009 Jan 30. PubMed PMID: 19184019; PubMed Central PMCID: PMC2717390

Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res. 2008 Nov 15;14(22):7367-77. doi: 10.1158/1078-0432.CCR-08-1016. PubMed PMID: 19010852; PubMed Central PMCID: PMC3109074

Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 4;99(9):1415-25. doi: 10.1038/sj.bjc.6604700. Epub 2008 Oct 7. PubMed PMID: 18841159; PubMed Central PMCID: PMC2576487

Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW. Development of human single-chain antibodies against SARS-associated coronavirus. Intervirology. 2008;51(3):173-81. doi: 10.1159/000151530. Epub 2008 Aug 25. PubMed PMID: 18724064

Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb 1;14(3):875-82. doi: 10.1158/1078-0432.CCR-07-1250. PubMed PMID: 18245551; PubMed Central PMCID: PMC2643368

Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, Montal M. Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem. 2008 Feb 15;283(7):3997-4003. Epub 2007 Nov 20. PubMed PMID: 18032388

Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007 Oct;6(10):2737-46. PubMed PMID: 17938267

Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007 Oct;30(7):684-93. PubMed PMID: 17893561

Varnum SM, Warner MG, Dockendorff B, Anheier NC Jr, Lou J, Marks JD, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ. Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Anal Chim Acta. 2006 Jun 16;570(2):137-43. Epub 2006 May 2. PubMed PMID: 17723391

Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol. 2007 Sep 1;179(5):2815-23. PubMed PMID: 17709495

Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007 Aug 24;371(4):934-47. Epub 2007 May 10. PubMed PMID: 17602702; PubMed Central PMCID: PMC4198021

Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med (Berl). 2007 Oct;85(10):1113-23. Epub 2007 Jun 7. PubMed PMID: 17554518

Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol. 2007 Jul;44(15):3777-88. Epub 2007 May 10. PubMed PMID: 17498801; PubMed Central PMCID: PMC2739904

Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol. 2007 Jan;25(1):107-16. Epub 2006 Dec 17. PubMed PMID: 17173035

Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N 4th, Park JW, Marks JD, Benz CC, Kirpotin DB. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm. 2006 Nov-Dec;3(6):726-36. PubMed PMID: 17140260

Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol. 2007 Jan 5;365(1):196-210. Epub 2006 Oct 3. PubMed PMID: 17059824; PubMed Central PMCID: PMC1994578

Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD. A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol. 2006 Oct 2;7:24. PubMed PMID: 17014727; PubMed Central PMCID: PMC1633733

Kehoe JW, Velappan N, Walbolt M, Rasmussen J, King D, Lou J, Knopp K, Pavlik P, Marks JD, Bertozzi CR, Bradbury AR. Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics. 2006 Dec;5(12):2350-63. Epub 2006 Sep 12. PubMed PMID: 16971384

Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol. 2006 Sep 29;362(4):733-42. Epub 2006 Jul 27. PubMed PMID: 16938310

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006 Jul 1;66(13):6732-40. PubMed PMID: 16818648

Varnum SM, Warner MG, Dockendorff B, Anheier NC, Lou J, Marks JD, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ. Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Anal Chim Acta. 2006 Jun 16; 570(2):137-43. PMID: 17723391.

Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF 3rd, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 2006 Mar 1;12(5):1599-605. PubMed PMID: 16533787

Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm. 2005 Dec;20(6):603-13. PubMed PMID: 16398612

Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther. 2006 Apr;13(7):646-51. PubMed PMID: 16341056

Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005 Sep;73(9):5450-7. PubMed PMID: 16113261; PubMed Central PMCID: PMC1231122

Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol. 2005 Aug 5;351(1):158-69. PubMed PMID: 16002090

Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog. 2005 Jan-Feb;21(1):221-32. PubMed PMID: 15903261

Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog. 2005 Jan-Feb;21(1):205-20. PubMed PMID: 15903260

Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005 Feb 15;65(4):1471-8. PubMed PMID: 15735035

Manoutcharian K, Acero G, Munguia ME, Becerril B, Massieu L, Govezensky T, Ortiz E, Marks JD, Cao C, Ugen K, Gevorkian G. Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. Neurobiol Dis. 2004 Oct;17(1):114-21. PubMed PMID: 15350972

Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 2004 Sep 1;64(17):6200-6. PubMed PMID: 15342405

Bradbury AR, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods. 2004 Jul;290(1-2):29-49. Review. PubMed PMID: 15261570

Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks JD, Foster KA. Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J Immunol Methods. 2004 May;288(1-2):55-60. PubMed PMID: 15183085

Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ. Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett. 2004 Apr 23;564(1-2):24-34. PubMed PMID: 15094038

Marks JD. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord. 2004 Mar;19 Suppl 8:S101-8. Review. PubMed PMID: 15027061

Marks JD. Antibody affinity maturation by chain shuffling. Methods Mol Biol. 2004;248:327-43. PubMed PMID: 14970506

Marks JD. Selection of internalizing antibodies for drug delivery. Methods Mol Biol. 2004;248:201-8. PubMed PMID: 14970498

Marks JD, Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol Biol. 2004;248:161-76. PubMed PMID: 14970495

Secco P, Ferretti M, Gioia D, Cesaro P, Bozzo C, Marks JD, Santoro C. Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron. J Immunol Methods. 2004 Feb 1;285(1):99-109. PubMed PMID: 14871539

Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15;64(2):704-10. PubMed PMID: 14744788

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003 Jun 15;63(12):3154-61. PubMed PMID: 12810643

Pavlik P, Siegel RW, Marzari R, Sblattero D, Verzillo V, Collins C, Marks JD, Bradbury A. Predicting antigenic peptides suitable for the selection of phage antibodies. Hum Antibodies. 2003;12(4):99-112. PubMed PMID: 15156098

Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol. 2002 Oct;32(10):2773-82. PubMed PMID: 12355429

Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118. PubMed PMID: 12183061

Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50. Epub 2002 Aug 12. PubMed PMID: 12177434; PubMed Central PMCID: PMC123259

O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD. Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol. 2002 Aug 2;321(1):49-56. PubMed PMID: 12139932

Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis. 2002 Jul 1;186(1):64-73. Epub 2002 Jun 14. PubMed PMID: 12089663

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002 Apr;8(4):1172-81. PubMed PMID: 11948130

Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002 Mar 15;317(1):73-83. PubMed PMID: 11916379

Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002 Feb 22;20(11-12):1640-8. PubMed PMID: 11858873

Lindquist EA, Marks JD, Kleba BJ, Stephens RS. Phage-display antibody detection of Chlamydia trachomatis-associated antigens. Microbiology. 2002 Feb;148(Pt 2):443-51. PubMed PMID: 11832508

Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD. Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol. 2002 Feb 1;315(5):1063-73. PubMed PMID: 11827476

Li X, Stuckert P, Bosch I, Marks JD, Marasco WA. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther. 2001 Aug;8(8):555-65. PubMed PMID: 11571533

Mullaney BP, Pallavicini MG, Marks JD. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun. 2001 Oct;69(10):6511-4. PubMed PMID: 11553596; PubMed Central PMCID: PMC98787

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001 Jul 6;74(1-3):95-113. PubMed PMID: 11489487

Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001 Jun 15;61(12):4750-5. PubMed PMID: 11406547

McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 2001 May 15;166(10):6112-7. PubMed PMID: 11342630

Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods. 2001 May 1;251(1-2):123-35. PubMed PMID: 11292488

Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW, Marks JD. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2682-7. PubMed PMID: 11226299; PubMed Central PMCID: PMC30198

Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods. 2001 Feb 1;248(1-2):17-30. PubMed PMID: 11223066

Marshall KW, Marks JD. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells. J Immunother. 2001 Jan-Feb;24(1):27-36. PubMed PMID: 11211146

Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun. 2001 Jan 12;280(1):274-9. PubMed PMID: 11162510

Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 2000 Nov 15;60(22):6434-40. PubMed PMID: 11103810

Sheridan RE, Deshpande SS, Amersdorfer P, Marks JD, Smith T. Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin. Toxicon. 2001 May;39(5):651-7. PubMed PMID: 11072043

Liu B, Marks JD. Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal Biochem. 2000 Nov 1;286(1):119-28. PubMed PMID: 11038282

Siegel RW, Allen B, Pavlik P, Marks JD, Bradbury A. Mass spectral analysis of a protein complex using single-chain antibodies selected on a peptide target: applications to functional genomics. J Mol Biol. 2000 Sep 15;302(2):285-93. PubMed PMID: 10970733

Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000 Sep 1;301(5):1149-61. PubMed PMID: 10966812

Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Litwin S, Marks JD, Weiner LM, Brechbiel MW. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol. 2000 May;27(4):339-46. PubMed PMID: 10938467

Nielsen UB, Marks JD. Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. Pharm Sci Technolo Today. 2000 Aug;3(8):282-291. PubMed PMID: 10916148

Amersdorfer P, Marks JD. Phage libraries for generation of anti-botulinum scFv antibodies. Methods Mol Biol. 2000;145:219-40. PubMed PMID: 10820725

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol. 1999 May;36(7):433-45. PubMed PMID: 10449096

Hughes-Jones NC, Bye JM, Gorick BD, Marks JD, Ouwehand WH. Synthesis of Rh Fv phage-antibodies using VH and VL germline genes. Br J Haematol. 1999 Jun;105(3):811-6. PubMed PMID: 10354152

Cirino NM, Sblattero D, Allen D, Peterson SR, Marks JD, Jackson PJ, Bradbury A, Lehnert BE. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect Immun. 1999 Jun;67(6):2957-63. PubMed PMID: 10338505; PubMed Central PMCID: PMC96606

Poul MA, Marks JD. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 1999 Apr 30;288(2):203-11. PubMed PMID: 10329137

Becerril B, Poul MA, Marks JD. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun. 1999 Feb 16;255(2):386-93. PubMed PMID: 10049718

McCall AM, Amoroso AR, Sautès C, Marks JD, Weiner LM. Characterization of anti-mouse Fc gamma RII single-chain Fv fragments derived from human phage display libraries. Immunotechnology. 1998 Jun;4(1):71-87. PubMed PMID: 9661816

Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 1998 May;77(9):1405-12. PubMed PMID: 9652755; PubMed Central PMCID: PMC2150193

Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindquist E, Schier R, Hemingsen G, Wong C, Gerhart JC, Marks JD. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6157-62. Erratum in: Proc Natl Acad Sci U S A 1999 Jan 19;96(2):795. Lindqvist E [corrected to Lindquist E]. PubMed PMID: 9600934; PubMed Central PMCID: PMC27609

Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 1998 Feb 1;58(3):485-90. PubMed PMID: 9458094

Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun. 1997 Sep;65(9):3743-52. PubMed PMID: 9284147; PubMed Central PMCID: PMC175534

Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, Stevens RC. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun. 1997 May;65(5):1626-30. PubMed PMID: 9125539; PubMed Central PMCID: PMC175186

Finnern R, Pedrollo E, Fisch I, Wieslander J, Marks JD, Lockwood CM, Ouwehand WH. Human autoimmune anti-proteinase 3 scFv from a phage display library. Clin Exp Immunol. 1997 Feb;107(2):269-81. PubMed PMID: 9030863; PubMed Central PMCID: PMC1904567

Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996 Nov 8;263(4):551-67. PubMed PMID: 8918938

Marks C, Marks JD. Phage libraries--a new route to clinically useful antibodies. N Engl J Med. 1996 Sep 5;335(10):730-3. Review. PubMed PMID: 8703174

Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks JD. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene. 1996 Mar 9;169(2):147-55. PubMed PMID: 8647439

Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol. 1996 Jan 12;255(1):28-43. PubMed PMID: 8568873

Schier R, Marks JD. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas. 1996;7(3):97-105. PubMed PMID: 9057057

Finnern R, Bye JM, Dolman KM, Zhao MH, Short A, Marks JD, Lockwood MC, Ouwehand WH. Molecular characteristics of anti-self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries. Clin Exp Immunol. 1995 Dec;102(3):566-74. PubMed PMID: 8536374; PubMed Central PMCID: PMC1553387

Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995 May;1(1):73-81. PubMed PMID: 9373335

Hughes-Jones NC, Gorick BD, Bye JM, Finnern R, Scott ML, Voak D, Marks JD, Ouwehand WH. Characterization of human blood group scFv antibodies derived from a V gene phage-display library. Br J Haematol. 1994 Sep;88(1):180-6. PubMed PMID: 7803241

Figini M, Marks JD, Winter G, Griffiths AD. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J Mol Biol. 1994 May 27;239(1):68-78. PubMed PMID: 8196048

Ouwehand WH, Bye JM, Gorick BD, Marks JD, Timmers E, Griffin HM, Finnern R, Hughes-Jones N. The humoral immune response against blood group antigens at the molecular level. Vox Sang. 1994;67 Suppl 3:7-12. Review. PubMed PMID: 7975514

Marks JD, Ouwehand WH, Bye JM, Finnern R, Gorick BD, Voak D, Thorpe SJ, Hughes-Jones NC, Winter G. Human antibody fragments specific for human blood group antigens from a phage display library. Biotechnology (N Y). 1993 Oct;11(10):1145-9. PubMed PMID: 7764095

Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, Baier M, Holliger KP, Gorick BD, Hughes-Jones NC, et al. Human anti-self antibodies with high specificity from phage display libraries. EMBO J. 1993 Feb;12(2):725-34. PubMed PMID: 7679990; PubMed Central PMCID: PMC413258

Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes. Rev Fr Transfus Hemobiol. 1993 Jan;36(1):19-47. Review. PubMed PMID: 8476490

Bye JM, Carter C, Cui Y, Gorick BD, Songsivilai S, Winter G, Hughes-Jones NC, Marks JD. Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift. J Clin Invest. 1992 Dec;90(6):2481-90. PubMed PMID: 1469099; PubMed Central PMCID: PMC443405

Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes. Immunol Rev. 1992 Dec;130:41-68. Review. PubMed PMID: 1286871

Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. Structural repertoire of the human VH segments. J Mol Biol. 1992 Oct 5;227(3):799-817. PubMed PMID: 1404389

Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol. 1992 Oct 5;227(3):776-98. PubMed PMID: 1404388

Marks JD, Hoogenboom HR, Griffiths AD, Winter G. Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system. J Biol Chem. 1992 Aug 15;267(23):16007-10. Review. PubMed PMID: 1644788

Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y). 1992 Jul;10(7):779-83. PubMed PMID: 1368267

Marks JD, Winter G. An artificial immune system for making antibodies. Behring Inst Mitt. 1992 Apr;(91):6-12. Review. PubMed PMID: 1524572

Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol. 1991 Dec 5;222(3):581-97. PubMed PMID: 1748994

Marks JD, Tristem M, Karpas A, Winter G. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur J Immunol. 1991 Apr;21(4):985-91. PubMed PMID: 2019291

Songsivilai S, Bye JM, Marks JD, Hughes-Jones NC. Cloning and sequencing of human lambda immunoglobulin genes by the polymerase chain reaction. Eur J Immunol. 1990 Dec;20(12):2661-6. PubMed PMID: 2125272

 

 

Photos
Contact

Zuckerberg San Francisco General Hospital, 3C-38
University of California, San Francisco
1001 Potrero Avenue
Bldg 1, Room 150
San Francisco, CA 94110
Email: [email protected]
Lab phone: 415-206-5940
Fax: 415-206-8170